老年难治性抑郁:双侧θ爆发刺激不劣于标准双侧rTMS
FOUR-D随机非劣效试验纳入60岁及以上难治性抑郁门诊患者,比较4-6周双侧标准rTMS与双侧TBS。主要终点蒙哥马利-奥斯伯格抑郁评定量表(MADRS)评分变化显示TBS不劣于rTMS(校正差异1.55,95%CI下限-0.67)。
要点
- 老年难治性抑郁中,双侧TBS在改善抑郁症状方面不劣于双侧标准rTMS。
- MADRS评分rTMS组由25.6降至17.3,TBS组由25.7降至15.8,校正差异1.55(95%CI下限-0.67)。
核心结论
- 在老年难治性抑郁患者中,与双侧标准rTMS相比,双侧TBS在减少抑郁症状方面达到非劣效。
- 两种治疗的全因脱落率均较低且相近。
研究设计与样本
- 纳入60岁及以上门诊抑郁症患者,病情中度严重,对1种及以上足量足疗程抗抑郁药试验无应答,或对2种及以上试验不耐受。
- 参与者随机接受4至6周双侧标准rTMS或双侧TBS治疗。
- 标准双侧rTMS组87人(平均年龄67.1岁,SD 6.7;女性47人,54.0%),TBS组85人(平均年龄66.3岁,SD 5.3;女性45人,52.9%)。
- 主要终点为MADRS评分变化,非劣效界值2.75分;所有达到4周主要完成点的参与者纳入分析。
主要发现
- MADRS总分均值(SD)在rTMS组从25.6(4.0)改善至17.3(8.9),TBS组从25.7(4.7)改善至15.8(9.1),校正差异1.55(95%CI下限-0.67),确立TBS非劣效。
- 主要终点评估人数:rTMS组85人(98%),TBS组79人(93%);耐受性在所有随机参与者中评估。
关键数值与推荐
- 主要终点非劣效界值为2.75分。
- MADRS评分校正差异1.55,95%CI下限-0.67,满足非劣效。
临床怎么用
- 在老年难治性抑郁门诊患者中,双侧TBS与双侧标准rTMS相比达到非劣效的抑郁症状改善。
- 两种治疗的全因脱落率均较低且相近。
- 使用TBS而非rTMS可能成倍增加老年难治性抑郁患者获得治疗的机会。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment-resistant depression (TRD) is common in older adults. Bilateral repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex for 48 minutes has demonstrated efficacy in TRD. Theta burst stimulation (TBS), a newer form of rTMS, can also be delivered bilaterally using left intermittent TBS and right continuous TBS for only 4 minutes. OBJECTIVE: To establish the effectiveness and tolerability of TBS compared with standard rTMS in older adults with TRD. DESIGN, SETTING, AND PARTICIPANTS: In this randomized noninferiority trial with open treatment and blinded assessors, recruitment occurred between December 2016 and March 2020. The trial was conducted at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada and included outpatients 60 years and older with a diagnosis of depression, moderate severity, and nonresponse to 1 or more antidepressant trial of adequate dosage and duration or intolerance of 2 or more trials. INTERVENTIONS: Participants were randomized to receive a course of 4 to 6 weeks of either bilateral standard rTMS or TBS. MAIN OUTCOMES AND MEASURES: The primary outcome measure was change in Montgomery-Åsberg Depression Rating Scale; secondary outcome measures included the 17-item Hamilton Rating Scale for Depression, Quick Inventory of Depressive Symptomatology (16-item) (self-report), and dropout rates. A noninferiority margin of 2.75 points was used for the primary outcome. All participants who attained the primary completion point of 4 weeks were analyzed. RESULTS: A total of 87 participants (mean [SD] age, 67.1 [6.7] years; 47 [54.0%] female) were randomized to standard bilateral rTMS and 85 (mean [SD] age, 66.3 [5.3] years; 45 [52.9%] female) to TBS, of whom 85 (98%) and 79 (93%) were assessed for the primary outcome, respectively, whereas tolerability was assessed in all randomized participants. In the rTMS group, 4 (4.6%) were American Indian, reported other, or preferred not to answer; 5 (5.8%) were Asian; and 78 (89.7%) were White. In the TBS group, 6 (7.1%) were Asian, 2 (2.4%) were Black or reported other, and 77 (90.3%) were White. Mean (SD) Montgomery-Åsberg Depression Rating Scale total scores improved from 25.6 (4.0) to 17.3 (8.9) for rTMS and 25.7 (4.7) to 15.8 (9.1) for TBS (adjusted difference, 1.55; lower 95% CI -0.67), establishing noninferiority for TBS. The all-cause dropout rates were relatively similar between groups (rTMS: 2 of 87 [2.3%]; TBS: 6 of 85 [7.1%]; P = .14; χ2 = 2.2). CONCLUSIONS AND RELEVANCE: In older adults with TRD, bilateral TBS compared with standard bilateral rTMS achieved noninferior reduction in depression symptoms. Both treatments had low and similar dropout rates. Using TBS rather than rTMS could increase access to treatment several-fold for older adults with TRD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02998580.
引用
- Blumberger DM, Mulsant BH, Thorpe KE, et al. Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression: The FOUR-D Randomized Noninferiority Clinical Trial. JAMA Psychiatry. 2022. PMID: 36129719. doi:10.1001/jamapsychiatry.2022.2862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。